Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.34 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 54.04 | Oscillator | Neutral |
| Williams %R (14) | -39.92 | Oscillator | Neutral |
| MACD (12, 26, 9) | -1.34 (Hist 0.45) | Oscillator | Buy |
| Average Directional Index (14) | 34.33 (+DI 12.2 / -DI 21.1) | Trend | Strong Sell |
| EMA 20 | 48.52 | MA | Buy |
| SMA 20 | 47.83 | MA | Buy |
| EMA 50 | 51.27 | MA | Strong Sell |
| SMA 50 | 52.70 | MA | Strong Sell |
| SMA 200 | 49.96 | MA | Sell |
Current price $48.73
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 30, 26 | JP Morgan | maintain | Overweight | Overweight |
| Sep 24, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 23, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Aug 25, 26 | TD Cowen | maintain | Buy | Buy |
| Aug 24, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 13, 26 | UBS | maintain | Buy | Buy |
| May 13, 26 | Barclays | maintain | Overweight | Overweight |
| May 4, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Apr 28, 26 | Leerink Partners | maintain | Outperform | Outperform |
TTM vs. 5-year historical average (annual ratios)
| Metric | ANAB | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 7.2x | -18.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 9.6x | EPS est. 5.07 | Elevated |
| Price / Book | 134.7x | 7.2x | Elevated |
| Price / Sales | 6.1x | 19.1x | Discount |
| EV / EBITDA | 17.3x | -1.2x | Discount |
| Return on equity | 2515.2% | — | Top tier |
| Gross margin | 133.1% | -294.1% | Below hist. |
| Debt / Equity | 25.47 | 1.19 | Levered |
| Piotroski / Altman Z | 5/9 | Z 2.32 | Grey zone |
Discounted cash flow model
Stock news · updated daily
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.
Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,500 shares of the biotechnology company's stock, valued at approximately $1,114,000. Canada Pension Plan Investment Board owned
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 21, 2026 | 5.11 | 5.11 | Beat 0.0% | $27.49M |
| May 12, 2026 | -0.32 | -1.84 | Miss -475.0% | $25.56M |
| Mar 3, 2026 | 0.89 | 1.58 | Beat 77.5% | $108.2M |
| Nov 4, 2025 | -1.06 | 0.52 | Beat 149.1% | $76.32M |
| Aug 7, 2025 | -1.50 | -1.34 | Beat 10.7% | $22.26M |
| May 5, 2025 | -1.30 | -1.28 | Beat 1.5% | $27.77M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 2, 2026 | 2026-10-02 17:47:56 | View |
| 10-KT | Sep 21, 2026 | 2026-09-21 16:23:41 | View |
| 8-K | Sep 21, 2026 | 2026-09-21 16:20:00 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:05:19 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 08:31:03 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 16:05:17 | View |
| 4 | Aug 7, 2026 | 2026-08-07 17:13:24 | View |
| 4 | Aug 7, 2026 | 2026-08-07 17:12:19 | View |
| 8-K | Jul 30, 2026 | 2026-07-30 16:05:15 | View |
| ARS | Jun 29, 2026 | 2026-06-29 16:08:39 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Renton Hollings | director | M-Exempt | 5,000 @ $18.03 | $90.15K |
| Oct 1, 26 | Renton Hollings | director | S-Sale | 5,000 @ $49.87 | $249.4K |
| Oct 1, 26 | Renton Hollings | director | M-Exempt | 5,000 @ $18.03 | $90.15K |
| Sep 15, 26 | Orwin John A | director | M-Exempt | 1,300 | — |
| Sep 15, 26 | Orwin John A | director | M-Exempt | 1,300 | — |
| Mar 12, 26 | Lizzul Paul F. | officer: Chief Medical Officer | A-Award | 16,667 | — |
| Mar 12, 26 | Faga Daniel | director, officer: President, CEO | A-Award | 53,334 | — |
| Jun 15, 26 | Schmid John P. | director | M-Exempt | 6,030 | — |